Clinical trail of Astragalus injection combined with low molecular heparin sodium in the treatment of patients with preeclampsia
10.13699/j.cnki.1001-6821.2018.01.003
- VernacularTitle:黄芪注射液联合低分子肝素钠治疗子痫前期患者的临床研究
- Author:
Juan LIN
1
;
Hong-Qiong GUAN
;
Chun-Yan YE
;
Ting-Na LI
;
Su-Jing HUANG
Author Information
1. 海南医学院第二附属医院产科
- Keywords:
Astragalus injection;
low molecular weight heparin sodium;
pre-eclampsia;
platelet membrane glycoprotein GP Ⅱ /Ⅲ alpha;
D-two dimer;
estrogen
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(1):10-13
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Astragalus injection combined with low molecular heparin sodium on patients with preeclampsia.Methods All total of 64 patients with preectampsia were selected from our hospital in accordance with the standards were selected and randomly divided into two groups,each group with 32 cases.The control group was treated with 25％ magnesium sulfate 25 mL + 5％glucose injection 20 mL,slow intravenous injection in 5-10 min,followed by 25％ magnesium sulfate 40 mL + 5％ glucose injection 500 mL,intravenous infusion with 1-2 g · h-1 dripping speed,the total volume of magnesium sulfate was 25 g,qd,continued treatmcnt for 1 week.The treatment group,on the basis of the control group,treated with low-molecular-weight heparin sodiun injection 4100 U,qd,subcutaneous injection;Astragalus injection 30 mL +0.9％ normal saline 250 mL,qd,intravenous drip,continued treatment for 1 week.The percentage of platelets positive for glycoprotein GP I1 / 111 α were detected by flow cytometry.The serum D-dimer values were measured by colloidal gold double antibody sandwich nethod.The serum level of estrogen (E2) was determined by enzyme-linked immunosorbent assay.Results After treatment,factors in the treatment group and the control group were as follows:the glycoprotein GP Ⅱ/Ⅲ α levels were (0.86 ± 0.39),(1.39 ± 0.41)％;serum D-dimer levels were (1.07 ±0.37),(1.49 ±0.41) mg · L-t,the serum E2 levels were(54.63 ± 8.64) and(47.82 ± 8.21) pmol · L-1,the differences between the two groups were statistically significant(all P ＜ 0.05).The pregnancy termination week in the treatment group and the control group were (32.51 ± 1.37),(31.26 ± 1.24) weeks;the neonatal body mass in the two groups were (1956.26 ± 142.36),(1824.63 ± 132.59) g.Compared with the control group,the differences were statistically significant (all P ＜ 0.05).The incidence rates of adverse drug reactions in treatment and control groups were respectively 31.25％ (10 cases/32 cases)and 40.63％ (13 cases/32 cases),there was no statistical difference between the two groups (P ＞ 0.05).Conclusion Astragalus injection combined with low molecular heparin sodium can safely and effectively improve the pregnancy outcome of preeclampsia pregnant women.
